



## Italian Bank Rescue: What is €5bn among friends? Not enough to pay for the first round of drinks...

Ticker	Rating	CUR	12 Apr 2016 Closing Price	Target Price	TTM Rel. Perf.	Cash EPS			P/B			Yield
						2014A	2015E	2016E	2014A	2015E	2016E	
ISP.IM	O	EUR	2.24	3.90	-12.6%	0.12	0.23	0.28	0.8	1.0	1.0	6.3%
UCG.IM	M	EUR	2.98	5.50	-36.8%	0.39	0.40	0.56	0.4	0.4	0.3	4.0%
MSDLE15			1320.15			94.04	86.54	87.69	NA	NA	NA	3.7%

O – Outperform, M – Market-Perform, U – Underperform, N – Not Rated

### Highlights

On Monday evening, among a lot of tension and anger, agreement was reached on the creation of the Atlas fund for the rescue of the Italian banking system. It's aptly named after Atlas, the god of endurance condemned to hold up the sky for eternity. One would need a similar deity to prevent the roof from caving in on the Italian banking system with only €5bn of spare change, the size of the fund. We have a quick look whether the numbers reported so far add up, or rather don't add up.

- **The Atlas fund: what is it?** It's a fund with a dual purpose: 1) to act as a backstop for capital raising banks who do not find buyers for their new share issues; 2) invest in the equity tranche of Bad Debt securitizations (the private Bad Banks that were approved by the EC). More detail in our quick-take yesterday [Quick Take - Italian Bank Rescue Plan... First Cut](#). The reported size of the fund is ~€5bn with ISP, UCG each contributing €1bn, insurers another €1bn, the foundations €0.5bn and the remainder made up of Popolare banks, CDP and SGA. *It was reported in the press that the fund would buy Bad Debt at close to the net book value.*
- **Is it enough to remove all Bad Debt from the Italian Banking system at book value? No.** At an overall system level, there is €360bn of Impaired Loans (NPLs) and €202bn of Bad Debt. Coverage on the former is ~45% and on the latter ~60%. So, at a system level there is ~€80bn of Net Bad Debt. If €5bn is the size of the equity tranche in the securitization vehicle, to buy ~€80bn of Net Bad Debt, we need 16x leverage or an equity tranche that is only 6.25%. 50% would come from state guaranteed senior notes and the remainder from mezzanine notes. We also need to make the unrealistic assumption that the IPO of BaVen and BPVi will need no intervention of the Atlas fund. None of this seems realistic.
- **Is it enough to at least remove the Bad Debt of ISP, UCG, BMPS, Carige and 8 Popolare<sup>1</sup> banks at book value? No.** The idea here is to fix the large banks first before taking on the tail of ~600 smaller Popolari and Co-ops. The Net Bad Debt at the large banks is ~€56bn. If we assume that the capital raise for BaVen (€1bn) and BPVi (€1.78bn) goes swimmingly and no back-stop intervention by the Atlas fund is required, it can invest the full €5bn in the equity tranche of the Bad Debt securitization vehicle. This would lead to 11x leverage (or 9% equity tranche) if all the Bad Debt is going to be bought at Net Book Value. Very unlikely. Things get worse when one considers the roof caving in on the BaVen and BPVi IPO requiring the Atlas fund in the worst case to pick up the tab of €2.76bn. In that case there would be only €2.24bn left to put into a Bad Debt securitization, leading to 25x leverage (or 4% equity tranche).

<sup>1</sup> BPE, CVAL, UBI, BPSO, PMI, BP, BPVi, BaVen

- **Taking the ambition level down further, is it sufficient to just buy the Bad Debt of the weakest large banks: BMPS, BP, Carige, BPVi, BPVen? Unlikely.** The Net Bad Debt of these 5 amounts to ~€19bn. If the full €5bn is pumped into the equity tranche of the Bad Debt securitization vehicle, we only need 4x leverage to buy the Net Bad Debt of these banks. Again we need to assume that no assistance will be needed for the IPO of BPVen and BPVi (see **Exhibit 1**).
- **For the Atlas fund to buy through the "Bad Bank" securitization vehicle the Bad Debt of the large Italian banks at Net Book Value is not only unrealistic, but essentially unfair.** Not all Bad Debt is created equal in Italy. There are large differences between banks. We look at Bad Debt along three dimensions: unsecured proportion, RE collateral level for secured Bad Debt and proportion of Bad Debt that resides in the South. Assuming a 15% unlevered return to the holders of the equity tranche in a Bad Debt securitization, 7 years recovery period for Bad Debt collateral (5 years for ISP and UCG) and 50% haircut on collateral in the South vs 10% haircut on collateral in North and Centre we derive the following "fair" sale prices for Bad Debt by bank (see **Exhibit 2**). On average the Net Book Value for Bad Debt is 40 cents/€ while we believe a "fair" disposal value through the "Bad Bank" securitization should be on average 30 cents/€ with large variation among the banks (see **Exhibit 4**).
- **How much should the Atlas fund size be under current debt collection horizon of on average 7 years? €20bn.** If we dispose the Bad Debt through the Bad Bank at our "fair" prices providing an unlevered return of 15% to holders of the equity tranche and assuming a recovery period of 7 years (except for ISP and UCG at 5 years), the Bad Bank securitization vehicle would pay €41bn for a Net Bad Debt of €56bn. This would lead to a recapitalization of the weakest banks (likely without access to capital markets) and UCG of about €10bn (see **Exhibit 5**). So, with 4x leverage in the securitization vehicle, one would need the Atlas fund to have €10bn as a backstop for the IPOs of UCG as well as BMPS, BP, Carige, BPVen and BPVi while putting in ~€10bn in the equity tranche of the Bad Debt securitization vehicle.
- **If Debt Collection can be shortened to 3 years on average and equity tranche investors do not require more than 10% IRR, the Atlas fund could make it work with €9bn.** Though unrealistic that Bad Debt collection could be sped up so fast in as short period of time (i.e. shortening by 4 years), the Atlas fund still requires almost double the current inlay of €5bn. Under this scenario, the securitization fund would buy at the current book value of Bad Debt, i.e. ~€56bn but make an instant profit of €9.4bn upon purchase (because of shorter recovery period and lower discount rate). At the same time, only €4.6bn in fresh capital would need to be raised at the weakest banks (which then do not include BMPS anymore). At 4x leverage, an equity tranche is needed of €14bn against which the profit net of backstop capitalization contribution €4.8bn (=€9.4 - €4.6) can be off-set so requiring an outlay of only ~€9bn by the Atlas fund.


### Investment Conclusion

We believe that the Atlas Fund for the Italian Bank Rescue is underfunded by €15bn on current 7 year recovery assumptions and a 15% discount rate and by €4bn on very optimistic 3 year recovery assumptions and a 10% discount rate. Given that any single bank's contribution cannot exceed 20% of the fund, this could mean that ISP and UCG see their contributions increase to €4bn each. It would reduce the upside for ISP as €4bn out of their €10bn surplus over and above the dividend program of €3bn in 2016 and €4bn in 2017 which will remain because paid out of earnings. For UCG, it may lead to a capital raise.

Our preference for ISP over UCG remains. ISP outperform, UCG marketperform.


**Details**

Exhibit 1  
**Net Bad Debt for the largest Italian banks is €56bn**



Source: Company reports, Bernstein analysis and estimates


Exhibit 2  
**Bad Debt average book value is 40 cents/€ versus estimated disposal price of €30 cents/€ on average**



Source: Company reports, Bernstein analysis and estimates

Exhibit 3

Net Bad Debt is €56bn in total versus "Fair" disposal price value of €41bn in total



Source: Company reports, Bernstein analysis and estimates

## Exhibit 4

## Bad Debt valuation along the three lenses and impact on TNAV

	ISP	UCG	BMPS	BPE	CVAL	UBI	BPSO	PMI	BP	BPVi	BaVen	CRG
<b>THREE LENSES ON BAD DEBT</b>												
<b>Lens 1: Secured vs Unsecured Bad Debt</b>												
Unsecured Net Bad Debt	16%	24%	22%	44%	33%	20%	18%	24%	13%	23%	23%	18%
<b>Lens 2: Cash &amp; RE Collateral Coverage Secured Bad Debt</b>												
Cash coverage Gross Secured Bad Debt	60%	60%	64%	34%	41%	17%	57%	48%	33%	50%	44%	58%
RE Collateral coverage Gross Secured Bad Debt	107%	83%	107%	234%	177%	197%	173%	183%	126%	53%	52%	53%
<b>Lens 3: Presence of Gross Bad Debt in the South</b>												
Bad Debt in the South as % of Total Gross Bad Debt	23%	29%	38%	48%	24%	13%	2%	8%	12%	22%	30%	8%
<b>ASSUMPTIONS</b>												
<b>Blended recovery cost as % collateral</b>												
Recovery costs North/Centre as %Collateral	19%	21%	25%	29%	20%	15%	11%	13%	15%	19%	22%	13%
Recovery costs South as % Collateral	10%	10%	10%	10%	10%	10%	10%	10%	10%	10%	10%	10%
Recovery costs South as % Collateral	50%	50%	50%	50%	50%	50%	50%	50%	50%	50%	50%	50%
<b>Recovery period</b>												
	5	5	7	7	7	7	7	7	7	7	7	7
<b>Investor discount rate applied to derive collateral NPV</b>												
	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%
<b>IMPACT ON TNAV</b>												
<b>Loss on Net Unsecured Bad Debt / TNAV</b>												
assume mkt price 10c/€ versus net book value of 30c/€	-3.6%	-5.5%	-23.0%	-18.7%	-13.5%	-6.7%	-3.0%	-4.9%	-8.9%	-11.3%	-9.8%	-7.0%
<b>Loss/Gain on Net Secured Bad Debt / TNAV</b>												
total loss on net secured loan / TNAV	2.4%	-5.0%	-21.4%	-2.3%	-3.4%	-9.8%	7.3%	3.4%	-34.3%	-39.1%	-35.4%	-28.9%
recovery of RE collateral / TNAV	-29.3%	-26.6%	-124.1%	-36.3%	-40.5%	-40.1%	-20.5%	-23.0%	-86.1%	-58.0%	-48.5%	-48.0%
	31.7%	21.6%	102.7%	34.0%	37.2%	30.2%	27.8%	26.4%	51.8%	18.8%	13.1%	19.1%
<b>Net Impact on TNAV</b>												
as % of TNAV	-1.2%	-10.4%	-44.4%	-21.0%	-16.9%	-16.5%	4.4%	-1.5%	-43.2%	-50.4%	-45.2%	-35.9%
in absolute € millions	(446)	(4,376)	(2,366)	(920)	(306)	(1,328)	104	(64)	(2,599)	(1,272)	(862)	(854)
per share in €	(0.03)	(0.73)	(0.81)	(1.91)	(0.28)	(1.47)	0.23	(0.01)	(7.18)	--	--	(1.03)
<b>Impact on CET1 capital</b>												
FL CET1 pre disposal	13.1%	10.9%	11.7%	11.2%	13.5%	11.6%	10.5%	12.2%	12.4%	5.9%	6.8%	11.5%
FL CET1 post disposal	13.0%	9.9%	8.6%	9.1%	11.8%	9.7%	10.9%	12.0%	7.0%	0.8%	3.2%	7.5%
Change in bps	(14)	(101)	(305)	(208)	(174)	(196)	39	(16)	(540)	(507)	(361)	(395)
<b>SALE PRICE BAD DEBT &amp; ADDITIONAL COVERAGE</b>												
additional coverage on Gross Bad Debt	1%	11%	10%	14%	12%	20%	-7%	2%	25%	29%	33%	24%
Book value of Bad Debt (cents/€)	38	37	35	44	44	61	40	44	58	43	47	40
Potential sale price of Bad Debt (cents/€)	36	26	25	29	32	41	47	42	33	14	13	15

Source: Company reports, Bernstein analysis and estimates

## Exhibit 5

## Capital Surplus and Shortfall after Bad Debt disposal on 7 year recovery and 15% discount rate

## Healthiest banks

In €bn

	FL CET1	FL RWA	Bad debt writedown	Adj. FL CET1 ratio	SREP req	Surplus (%)	Surplus
ISP	37	284	0.4	13.0%	9.5%	3.5%	9.8
UCG	43	391	4.4	9.9%	10.8%	-0.8%	(3.2)
UBI	7	61	1.3	9.7%	9.3%	0.4%	0.3
<b>Total</b>	<b>87</b>	<b>736</b>					<b>6.9</b>

## Weakest banks

In €bn

	FL CET1	FL RWA	Bad debt writedown	Adj. FL CET1 ratio	SREP req	Shortfall (%)	Shortfall	Capital raise announced	Shortfall
BMPS	8	71	2.4	8.6%	10.2%	-1.6%	(1.1)	-	(1.1)
BPVi	1	25	1.3	0.8%	10.3%	-9.5%	(2.4)	(1.8)	(2.4)
BaVen	2	23	0.9	3.2%	10.3%	-7.0%	(1.6)	(1.0)	(1.6)
CRG	2	20	0.9	7.5%	11.3%	-3.7%	(0.7)	-	(0.7)
BP	6	45	2.6	7.0%	9.6%	-2.6%	(1.1)	(1.0)	(1.1)
<b>Total</b>	<b>19</b>	<b>184</b>							<b>(7.0)</b>

## Other banks

In €bn

	FL CET1	FL RWA	Bad debt writedown	Adj. FL CET1 ratio	SREP req	Surplus (%)	Surplus
BPE	4	40	0.9	9.1%	9.3%	-0.1%	(0.0)
CVAL	2	15	0.3	11.8%	8.3%	3.5%	0.5
BPSO	3	24	(0.1)	10.9%	9.3%	1.6%	0.4
PMI	4	35	0.1	12.0%	9.0%	3.0%	1.1
<b>Total</b>	<b>13</b>	<b>114</b>					<b>1.9</b>

Source: Company reports, Bernstein analysis and estimates

## Exhibit 6

**Capital Surplus and Shortfall after Bad Debt disposal on 3 year recovery and 10% discount rate****Healthiest banks***In €bn*

	FL CET1	FL RWA	Bad debt writedown	Adj. FL CET1 ratio	SREP req	Surplus (%)	Surplus
ISP	37	284	(5.6)	14.8%	9.5%	5.3%	15.0
UCG	43	391	(0.3)	11.0%	10.8%	0.2%	1.0
UBI	7	61	(0.1)	11.8%	9.3%	2.5%	1.6
<b>Total</b>	<b>87</b>	<b>736</b>					<b>17.6</b>

**Weakest banks***In €bn*

	FL CET1	FL RWA	Bad debt writedown	Adj. FL CET1 ratio	SREP req	Shortfall (%)	Shortfall	Capital raise announced	Shortfall
BMPS	8	71	(3.1)	15.4%	10.2%	5.2%	3.7	-	-
BPVi	1	25	0.8	2.8%	10.3%	-7.5%	(1.9)	(1.8)	(1.9)
BaVen	2	23	0.6	4.3%	10.3%	-6.0%	(1.4)	(1.0)	(1.4)
CRG	2	20	0.4	9.7%	11.3%	-1.6%	(0.3)	-	(0.3)
BP	6	45	(0.5)	13.4%	9.6%	3.8%	1.7	(1.0)	(1.0)
<b>Total</b>	<b>19</b>	<b>184</b>							<b>(4.6)</b>

**Other banks***In €bn*

	FL CET1	FL RWA	Bad debt writedown	Adj. FL CET1 ratio	SREP req	Surplus (%)	Surplus
BPE	4	40	0.0	11.2%	9.3%	1.9%	0.8
CVAL	2	15	(0.3)	15.0%	8.3%	6.7%	1.0
BPSO	3	24	(0.6)	12.6%	9.3%	3.4%	0.8
PMI	4	35	(0.7)	14.0%	9.0%	5.0%	1.7
<b>Total</b>	<b>13</b>	<b>114</b>					<b>4.4</b>

Source: Company reports, Bernstein analysis and estimates

**Links to previous Italian Bad Debt reports**[Quick Take - Italian Bank Rescue Plan... First Cut](#)[Italian banks: desperation and urgency lead to Robin Hood method - steal from the rich, give to the poor...](#)[Italian Bad Debt \(Part III\): What should be the "floor" under the share price after full Bad Debt disposal?](#)[Italian Bad Debt \(Part II\): Bad Debt sale price per bank...Whose TNAV is hit by a quick Bad Debt disposal?](#)[Italian Bad Debt \(Part I\): Until Debt do us part...PMI & BP the merger that cannot be allowed to fail...](#)

## Disclosure Appendix

**Valuation Methodology**

We apply the following valuation approach to arrive at our price targets:

We look at the 2017 Return on Tangible Book (RoTNAV) and Growth (g) as key drivers of value. We have found that returns are the single largest driver of valuation across our coverage.

We use the formula below to derive our target P / TNAV:

$$P/TNAV = (RoTNAV - g) / (Ke - g)$$

We adjust our estimated RoTNAV for Basel III fully loaded capital requirements to reflect the true profitability of the business once Basel III requirements are fully implemented.

We have not placed any value on growth for our coverage as deleveraging in Western Europe, sluggish growth in emerging markets and regulatory uncertainty will continue to weigh on growth in the near to medium term.

We use a market implied historical long-term average Cost of Equity (Ke) for our coverage.

We then apply our target P/TNAV multiple to our forecast of 2016E TNAV and to this we add the estimated excess capital per share at the end of 2016 to arrive at our Target Price.

For UCG we apply a litigation discount based on our estimate of potential litigation liabilities arising out of investigations such as interest rate and foreign exchange manipulation as well as violation of US sanctions.

Before we added a normalization option value to the price derived from the Gordon Growth calculation above. This normalization option reflected the upside from Cost of Risk normalization in Italy over a longer term time horizon discounted to end 2016. This has now been taken out as the improved Cost of Risk falls within the valuation horizon and thus is part of the actual model.

**Risks****Downside risk**

- Governmental and regulatory headwinds in CEE and Austria leading to additional levies, taxes, capital buffers and forced CHF loan conversion (for UCG)
- Additional loan loss provisioning under IFRS9 rules
- Impact of risk weight harmonization under Basel 4
- Credit costs are higher than our estimates if the Italian economy takes a turn for the worse
- Introduction of bank levy in Poland (for UCG)
- Execution risk in cost reduction program (mainly for UCG)

**Upside risk**

- Deferred tax credits eligible as CET1 capital if Italy follows Spain example.
- Exits from businesses leads to higher than expected capital savings (Ukraine / Austria) (for UCG)
- Merger of Pioneer – Santander Asset management leads to +25bps impact on capital (for UCG)

Management is able to meet targets on NII and net fees



*European Banking*

## SRO REQUIRED DISCLOSURES

- References to "Bernstein" relate to Sanford C. Bernstein & Co., LLC, Sanford C. Bernstein Limited, Sanford C. Bernstein (Hong Kong) Limited 盛博香港有限公司, and Sanford C. Bernstein (business registration number 53193989L), a unit of AllianceBernstein (Singapore) Ltd. which is a licensed entity under the Securities and Futures Act and registered with Company Registration No. 199703364C, collectively.
- Bernstein analysts are compensated based on aggregate contributions to the research franchise as measured by account penetration, productivity and proactivity of investment ideas. No analysts are compensated based on performance in, or contributions to, generating investment banking revenues.
- Bernstein rates stocks based on forecasts of relative performance for the next 6-12 months versus the S&P 500 for stocks listed on the U.S. and Canadian exchanges, versus the MSCI Pan Europe Index for stocks listed on the European exchanges (except for Russian companies), versus the MSCI Emerging Markets Index for Russian companies and stocks listed on emerging markets exchanges outside of the Asia Pacific region, and versus the MSCI Asia Pacific ex-Japan Index for stocks listed on the Asian (ex-Japan) exchanges - unless otherwise specified. We have three categories of ratings:

Outperform: Stock will outpace the market index by more than 15 pp in the year ahead.

Market-Perform: Stock will perform in line with the market index to within +/-15 pp in the year ahead.

Underperform: Stock will trail the performance of the market index by more than 15 pp in the year ahead.

Not Rated: The stock Rating, Target Price and/or estimates (if any) have been suspended temporarily.

- As of 04/12/2016, Bernstein's ratings were distributed as follows: Outperform - 48.7% (0.7% banking clients) ; Market-Perform - 41.3% (0.4% banking clients); Underperform - 9.9% (0.0% banking clients); Not Rated - 0.0% (0.0% banking clients). The numbers in parentheses represent the percentage of companies in each category to whom Bernstein provided investment banking services within the last twelve (12) months.
- The following companies are or during the past twelve (12) months were clients of Bernstein, which provided non-investment banking-securities related services and received compensation for such services ISP.IM / Intesa Sanpaolo SpA.
- An affiliate of Bernstein received compensation for non-investment banking-securities related services from the following companies ISP.IM / Intesa Sanpaolo SpA.

### 12-Month Rating History as of 04/11/2016

#### Ticker Rating Changes


ISP.IM	O (IC)	09/02/14
UCG.IM	M (RC)	11/26/15
	O (IC)	09/02/14

Rating Guide: O - Outperform, M - Market-Perform, U - Underperform, N - Not Rated  
 Rating Actions: IC - Initiated Coverage, DC - Dropped Coverage, RC - Rating Change

#### ISP.IM / Intesa Sanpaolo SpA

Date	Rating	Target(EUR)
09/02/14	O(IC)	2.90
03/05/15	O	3.10
04/24/15	O	3.90


IC - Initiated Coverage



## UCG.IM / UniCredit SpA

Date	Rating	Target(EUR)
09/02/14	O(IC)	7.40
10/13/14	O	7.45
01/09/15	O	7.60
02/03/15	O	7.00
04/24/15	O	7.60
11/26/15	M	5.70

IC - Initiated Coverage



## OTHER DISCLOSURES

A price movement of a security which may be temporary will not necessarily trigger a recommendation change. Bernstein will advise as and when coverage of securities commences and ceases. Bernstein has no policy or standard as to the frequency of any updates or changes to its coverage policies. Although the definition and application of these methods are based on generally accepted industry practices and models, please note that there is a range of reasonable variations within these models. The application of models typically depends on forecasts of a range of economic variables, which may include, but not limited to, interest rates, exchange rates, earnings, cash flows and risk factors that are subject to uncertainty and also may change over time. Any valuation is dependent upon the subjective opinion of the analysts carrying out this valuation.

Bernstein produces a number of different types of research product including, among others, fundamental analysis and quantitative analysis. Recommendations contained within one type of research product may differ from recommendations contained within other types of research product, whether as a result of differing time horizons, methodologies or otherwise.

This document may not be passed on to any person in the United Kingdom (i) who is a retail client (ii) unless that person or entity qualifies as an authorised person or exempt person within the meaning of section 19 of the UK Financial Services and Markets Act 2000 (the "Act"), or qualifies as a person to whom the financial promotion restriction imposed by the Act does not apply by virtue of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, or is a person classified as an "professional client" for the purposes of the Conduct of Business Rules of the Financial Conduct Authority.

**To our readers in the United States:** Sanford C. Bernstein & Co., LLC is distributing this publication in the United States and accepts responsibility for its contents. Any U.S. person receiving this publication and wishing to effect securities transactions in any security discussed herein should do so only through Sanford C. Bernstein & Co., LLC.

**To our readers in the United Kingdom:** This publication has been issued or approved for issue in the United Kingdom by Sanford C. Bernstein Limited, authorised and regulated by the Financial Conduct Authority and located at 50 Berkeley Street, London W1J 8SB, +44 (0)20-7170-5000.

**To our readers in member states of the EEA:** This publication is being distributed in the EEA by Sanford C. Bernstein Limited, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority and holds a passport under the Markets in Financial Instruments Directive.

**To our readers in Hong Kong:** This publication is being distributed in Hong Kong by Sanford C. Bernstein (Hong Kong) Limited 盛博香港有限公司, which is licensed and regulated by the Hong Kong Securities and Futures Commission (Central Entity No. AXC846). This publication is solely for professional investors only, as defined in the Securities and Futures Ordinance (Cap. 571).

**To our readers in Singapore:** This publication is being distributed in Singapore by Sanford C. Bernstein, a unit of AllianceBernstein (Singapore) Ltd., only to accredited investors or institutional investors, as defined in the Securities and Futures Act (Chapter 289). Recipients in Singapore should contact AllianceBernstein (Singapore) Ltd. in respect of matters arising from, or in connection with, this publication. AllianceBernstein (Singapore) Ltd. is a licensed entity under the Securities and Futures Act and registered with Company Registration No. 199703364C. It is regulated by the Monetary Authority of Singapore and located at One Raffles Quay, #27-11 South Tower, Singapore 048583, +65-62304600. The business name "Bernstein" is registered under business registration number 53193989L.

**To our readers in the People's Republic of China:** The securities referred to in this document are not being offered or sold and may not be offered or sold, directly or indirectly, in the People's Republic of China (for such purposes, not including the Hong Kong and Macau Special Administrative Regions or Taiwan), except as permitted by the securities laws of the People's Republic of China.

**To our readers in Japan:** This document is not delivered to you for marketing purposes, and any information provided herein should not be construed as a recommendation, solicitation or offer to buy or sell any securities or related financial products.

For the institutional client readers in Japan who have been granted access to the Bernstein website by Daiwa Securities Group Inc. ("Daiwa"), your access to this document should not be construed as meaning that Sanford C Bernstein is providing you with investment advice for any purposes. Whilst Sanford C Bernstein has prepared this document, your relationship is, and will remain with, Daiwa, and Sanford C Bernstein has neither any contractual relationship with you nor any obligations towards you.

**To our readers in Australia:** Sanford C. Bernstein & Co., LLC, Sanford C. Bernstein Limited and Sanford C. Bernstein (Hong Kong) Limited 盛博香港有限公司 are exempt from the requirement to hold an Australian financial services licence under the Corporations Act 2001 in respect of the provision of the following financial services to wholesale clients:

- providing financial product advice;
- dealing in a financial product;
- making a market for a financial product; and
- providing a custodial or depository service.

Sanford C. Bernstein & Co., LLC., Sanford C. Bernstein Limited, Sanford C. Bernstein (Hong Kong) Limited 盛博香港有限公司 and AllianceBernstein (Singapore) Ltd. are regulated by, respectively, the Securities and Exchange Commission under U.S. laws, by the Financial Conduct Authority under U.K. laws, by the Hong Kong Securities and Futures Commission under Hong Kong laws, and by the Monetary Authority of Singapore under Singapore laws, all of which differ from Australian laws.

One or more of the officers, directors, or employees of Sanford C. Bernstein & Co., LLC, Sanford C. Bernstein Limited, Sanford C. Bernstein (Hong Kong) Limited 盛博香港有限公司, Sanford C. Bernstein (business registration number 53193989L), a unit of AllianceBernstein (Singapore) Ltd. which is a licensed entity under the Securities and Futures Act and registered with Company Registration No. 199703364C, and/or their affiliates may at any time hold, increase or decrease positions in securities of any company mentioned herein.

Bernstein or its affiliates may provide investment management or other services to the pension or profit sharing plans, or employees of any company mentioned herein, and may give advice to others as to investments in such companies. These entities may effect transactions that are similar to or different from those recommended herein.

Bernstein Research Publications are disseminated to our customers through posting on the firm's password protected website, [www.bernsteinresearch.com](http://www.bernsteinresearch.com). Additionally, Bernstein Research Publications are available through email, postal mail and commercial research portals. If you wish to alter your current distribution method, please contact your salesperson for details.

Bernstein and/or its affiliates do and seek to do business with companies covered in its research publications. As a result, investors should be aware that Bernstein and/or its affiliates may have a conflict of interest that could affect the objectivity of this publication. Investors should consider this publication as only a single factor in making their investment decisions.

This publication has been published and distributed in accordance with Bernstein's policy for management of conflicts of interest in investment research, a copy of which is available from Sanford C. Bernstein & Co., LLC, Director of Compliance, 1345 Avenue of the Americas, New York, N.Y. 10105, Sanford C. Bernstein Limited, Director of Compliance, 50 Berkeley Street, London W1J 8SB, United Kingdom, or Sanford C. Bernstein (Hong Kong) Limited 盛博香港有限公司, Director of Compliance, Suites 3206-11, 32/F, One International Finance Centre, 1 Harbour View Street, Central, Hong Kong, or Sanford C. Bernstein (business registration number 53193989L), a unit of AllianceBernstein (Singapore) Ltd. which is a licensed entity under the Securities and Futures Act and registered with Company Registration No. 199703364C, Director of Compliance, 30 Cecil Street, #28-08 Prudential Tower, Singapore 049712. Additional disclosures and information regarding Bernstein's business are available on our website [www.bernsteinresearch.com](http://www.bernsteinresearch.com).

## CERTIFICATIONS

- I/(we), Johan De Mulder, Senior Analyst(s)/Analyst(s), certify that all of the views expressed in this publication accurately reflect my/(our) personal views about any and all of the subject securities or issuers and that no part of my/(our) compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views in this publication.

Approved By: RP

---

Copyright 2016, Sanford C. Bernstein & Co., LLC, Sanford C. Bernstein Limited, Sanford C. Bernstein (Hong Kong) Limited 盛博香港有限公司, and AllianceBernstein (Singapore) Ltd., subsidiaries of AllianceBernstein L.P. ~1345 Avenue of the Americas ~ NY, NY 10105 ~212/756-4400. All rights reserved.

This publication is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of, or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject Bernstein or any of their subsidiaries or affiliates to any registration or licensing requirement within such jurisdiction. This publication is based upon public sources we believe to be reliable, but no representation is made by us that the publication is accurate or complete. We do not undertake to advise you of any change in the reported information or in the opinions herein. This publication was prepared and issued by Bernstein for distribution to eligible counterparties or professional clients. This publication is not an offer to buy or sell any security, and it does not constitute investment, legal or tax advice. The investments referred to herein may not be suitable for you. Investors must make their own investment decisions in consultation with their professional advisors in light of their specific circumstances. The value of investments may fluctuate, and investments that are denominated in foreign currencies may fluctuate in value as a result of exposure to exchange rate movements. Information about past performance of an investment is not necessarily a guide to, indicator of, or assurance of, future performance.